Results 21 to 30 of about 13,103,023 (178)

Chemical Space of Fluorinated Nucleosides/Nucleotides in Biomedical Research and Anticancer Drug Discovery

open access: yesChemistry
Fluorinated nucleos(t)ide drugs have proven to be successful chemotherapeutic agents in treating various cancers. The Food and Drug Administration (FDA) has approved several drugs that fit within the fluorinated nucleoside pharmacophore, and many more ...
Yugandhar Kothapalli   +4 more
doaj   +2 more sources

Stopping nucleos(t)ide analog treatment in chronic hepatitis B — Who and when?

open access: yesLiver Research, 2017
Nucleos(t)ide analogs (NAs) are one of the first-line treatments for chronic hepatitis B (CHB) infection. NAs are highly efficient in suppressing viral replication but are associated with a low rate of hepatitis B surface antigen (HBsAg) seroclearance ...
Suzette Grace R. Kho-Herman   +1 more
doaj   +2 more sources

Factors associated with adherence to nucleos(t)ide analogs in chronic hepatitis B patients: results from a 1-year follow-up study

open access: yesPatient Preference and Adherence, 2015
Jie Peng, Junhua Yin, Shaohang Cai, Tao Yu, Chunxiu Zhong Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong Province, People’s Republic of China Abstract: Little is known about the factors associated with patient compliance with
Peng J, Yin JH, Cai SH, Yu T, Zhong CX
doaj   +1 more source

Clinical and virological efficacy of etravirine plus two active Nucleos(t)ide analogs in an heterogeneous HIV-infected population. [PDF]

open access: yesPLoS ONE, 2014
Etravirine (ETV) is recommended in combination with a boosted protease inhibitor plus an optimized background regimen for salvage therapy, but there is limited experience with its use in combination with two nucleos(t)ide reverse-transcriptase inhibitors
Luis F López-Cortés   +13 more
doaj   +3 more sources

Corrigendum: Increasing Number of Individuals Receiving Hepatitis B nucleos(t)ide Analogs Therapy in Germany, 2008-2019. [PDF]

open access: yesFront Public Health, 2022
Maisa A   +8 more
europepmc   +2 more sources

Monitoring and comorbidities in patients with chronic hepatitis B currently treated with nucleos(t)ide analogs. [PDF]

open access: yesAnn Gastroenterol, 2021
Long-term monotherapy with nucleos(t)ide analogs (NAs) represents the treatment option for the majority of patients with chronic hepatitis B (CHB), an aging population with a greater likelihood of comorbidities. We assessed the prevalence of concurrent non-hepatic diseases and the safety monitoring in a large cohort of CHB patients receiving NAs and ...
Siakavellas S   +10 more
europepmc   +4 more sources

Monitoring Adherence and Renal Safety of Nucleos(t)ide Analogs for Patients With Chronic Hepatitis B. [PDF]

open access: yesClin Transl Gastroenterol
INTRODUCTION: Entecavir (ETV), tenofovir disoproxil fumarate (TDF), and tenofovir alafenamide (TAF) are first-line nucleos(t)ide analogs (NA) for chronic hepatitis B (CHB). Real-world monitoring of patients on these agents and their comparative renal safety remain poorly characterized.
Hsu CC   +8 more
europepmc   +4 more sources

Lack of Pharmacokinetic Drug-Drug Interactions Between Bepirovirsen and Nucleos(t)ide Analogs. [PDF]

open access: yesClin Pharmacol Drug Dev
AbstractBepirovirsen is an antisense oligonucleotide currently in Phase 3 development to treat chronic hepatitis B virus (HBV) infection. Given the importance of coadministration of bepirovirsen and standard‐of‐care nucleos(t)ide analogs (NAs), we evaluated drug–drug interactions (DDIs) between bepirovirsen, entecavir (ETV), and tenofovir (TFV) using ...
Han K   +8 more
europepmc   +3 more sources

Home - About - Disclaimer - Privacy